A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...
After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...
The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...
The Fremont company sold extra shares at the top of its proposed range, and the stock jumped more than 30% in initial trading ...
Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...
From the Capital of France to the Capital of New York — a cutting-edge biotech firm that uses AI to research cancer ...
Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...
Investor's Business Daily on MSN
Four biotech stocks near buy points as earnings season kicks in
Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...
Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
In this article, we will be taking a look at the 10 Best Biotech Stocks Under $10 to Buy. According to Eli Casdin, CEO of ...
13hon MSN
Windlas Biotech announces Rs 47 crore buyback at Rs 1,000/share; sets April 24 as record date
Windlas Biotech approved a Rs 47 crore share buyback at Rs 1,000 per share via the tender route, with April 24 set as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results